Firms
BioMedPartners
Elisabethenanlage 11, 4051 Basel, Switzerland
BioMedPartners AG is a Basel-based Swiss life-sciences venture investment manager founded in 2002 according to its current own website and the Swiss Biotech Association directory. Historical fund releases and partner biographies sometimes date investment operations to 2003; that operational-history difference is explicitly retained. The exact legal manager is identified as CHE-109.704.295 in official Swiss commercial-register publications. It invests in biotechnology, pharmaceuticals, diagnostics and medical technology in Switzerland and neighboring European countries, often leading or co-leading early-to-mid-stage rounds. Its neuroscience relevance includes Noema Pharma’s investigational treatments for central-nervous-system disorders and Aleva Neurotherapeutics’ deep-brain-stimulation technology. Its BioMedInvest I–III portfolio is currently described as in the harvesting phase. The public team filter specifically identifies Markus Hosang, Michael Wacker, Thomas Möller, Valentin Piëch and Stefan Fäs with BioMedPartners; overlapping staff are distinguished from the separate successor BiomedVC AG, established in 2021 to manage newer early-stage investments and Fund IV. Historical 2020 Noema funding remains attributed to BioMedPartners rather than migrating to the later corporation. BioMedInvest I is primary-confirmed at CHF100M with a 2003 closing year; Fund II is CHF106M with a 2009 closing year; Fund III finally closed at CHF100M on March1,2018. Where only a year is published, exact close dates stay unknown. BioMedCredit is a historically documented separate mezzanine vehicle; a 2009 original profile reported CHF50M and a 2006 close, but no independently retrievable own final-close notice has been verified, so its numeric fund-close fields remain unknown. Aggregate committed capital and AUM are not added as another fund. The authentic historical green-diamond brand mark is retrieved from an explicitly labeled external logo mirror linked to the firm’s own LinkedIn identity; the original firm-hosted historical asset is unavailable. This is distinct from current BiomedVC’s own wordmark and unrelated US BioMed Ventures.
- Founded
- 2002
- Type
- Venture capital
Funds4
Team
Operations and support
 Markus HosangManaging Partner · Vice-Chair, statutory board (2021 official appointment confirmation) |
 Michael WackerManaging Partner · Statutory Board Director (2021 official appointment confirmation) |
 Stefan FäsCFO, Partner |
 Thomas MöllerManaging Partner |
 Ulrich VischerChair of statutory board (appointment last directly verified in November 2018) |
 Valentin PiëchManaging Partner |
Co-investing
Noema PharmaCHF 27M · 2024-12-11- Noema PharmaCHF 54M · 2020-12-01
Polaris Partners- Noema PharmaCHF 27M · 2024-12-11
- Noema PharmaCHF 54M · 2020-12-01
Sofinnova Partners- Noema PharmaCHF 27M · 2024-12-11
- Noema PharmaCHF 54M · 2020-12-01
The Invus Group, LLC- Noema PharmaCHF 27M · 2024-12-11
- Noema PharmaCHF 54M · 2020-12-01
EQT Life Sciences- Noema PharmaCHF 27M · 2024-12-11
- Noema PharmaCHF 27M · 2024-12-11
Jeito Capital- Noema PharmaCHF 27M · 2024-12-11
UPMC Enterprises- Noema PharmaCHF 27M · 2024-12-11